The pharmaceutical company, which focuses on developing therapeutics for endocrine diseases and endocrine-related tumors, also plans to grant underwriters a 30-day option to purchase up to an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback